The U.S. Food and Drug Administration lists both CJC-1295 and Ipamorelin on the 503A Category 2 bulk drug substances list as of April 2026. Secondary regulatory analysis confirms this administrative classification bars pharmacies from compounding the combination under Section 503A of the Federal Food, Drug, and Cosmetic Act.Superpower: CJC-1295 and Ipamorelin: Mechanism & Research No FDA-approved New Drug Application covers either peptide. No published human randomized controlled trial has tested the specific CJC-1295 plus Ipamorelin pairing.Superpower: CJC-1295 and Ipamorelin: Mechanism & Research
A pharmacy cannot lawfully compound the stack for patient use while the Category 2 review remains open. Prescribers evaluating the combination must recognize that the statutory pathway does not exist regardless of historical component access. Commercial availability now relies solely on unregulated research chemical vendors or non-compliant entities.
503A Category 2 Designation
Category 2 designation applies when the FDA identifies a bulk drug substance as presenting potential safety risks or lacking sufficient evidence to support compounding. The agency maintains this list as part of its oversight of Section 503A traditional compounding pharmacies. Placement on Category 2 means the substance cannot be compounded while the agency review continues.Superpower: CJC-1295 and Ipamorelin: Mechanism & Research
A 503A pharmacy that compounds CJC-1295 with Ipamorelin operates outside statutory authority. A prescriber writing for the combination cannot point to a lawful supply chain for fulfillment. The Category 2 listing removes the enforcement discretion that compounding pharmacies otherwise rely on for nominated substances.
This regulatory status represents an affirmative administrative finding of insufficient evidence or identified risk. It differs from Category 1 substances the FDA has evaluated and found suitable for compounding. It also differs from substances that have simply not been nominated for review.
Evidence Gap in Combination Therapy
The mechanistic rationale for combining CJC-1295 and Ipamorelin is coherent. CJC-1295 acts as a growth hormone-releasing hormone analog at the GHRH receptor. Ipamorelin acts as a ghrelin mimetic at the ghrelin receptor. Activating both pathways simultaneously produces a growth hormone pulse that neither compound generates alone.Inovi Fertility: CJC-1295 + Ipamorelin Fertility Hormone Regulation, Benefits & Safety
Mechanism does not constitute clinical proof. No published human randomized controlled trial of the specific CJC-1295 plus Ipamorelin combination exists as of April 2026. The synergy argument derives from individual component pharmacology and studies of related GHRH plus GHRP pairings rather than direct combination trials.Superpower: CJC-1295 and Ipamorelin: Mechanism & Research
Anderson Longevity Clinic claims benefits including increased muscle mass, improved fat loss, better sleep, and enhanced recovery.Anderson Longevity Clinic: CJC-1295 / Ipamorelin Peptide Therapy Information These claims trace to clinic marketing materials and provider observations rather than major trials. Inovi Fertility states plainly that no long-term human data exists on reproductive risks while acknowledging theoretical cancer concerns regarding IGF-1 elevation.Inovi Fertility: CJC-1295 + Ipamorelin FAQ
Perfect B Medical acknowledges its dosing protocol is not the outcome of a Phase III trial. There is no control group, IRB approval, or peer review behind the published regimen.Perfect B: CJC-1295/Ipamorelin Dosage Protocol For comparison of regulatory histories within this class, see cjc 1295 vs sermorelin and ipamorelin vs ghrp.
Research Grade Supply Liability
Remaining supply moves through channels labeled as research grade because the 503A pathway is closed. American Peptides lists CJC-1295 (NO DAC) plus Ipamorelin explicitly for laboratory research use only.American Peptides: CJC-1295 (NO DAC) + IPAMORELIN This labeling does not eliminate liability for clinical application.
Scientific American reported that an unpublished analysis found between 40% and 70% of gray-market peptide samples failed basic quality criteria. This failure rate included samples identified as CJC-1295 and Ipamorelin.Scientific American: Growth hormone peptides promise to stall aging—but does the science stack up? The absence of current good manufacturing practice standards creates distinct exposure for prescribers sourcing from these vendors.
The regulatory framework applies differently to approved peptides such as tesamorelin. Tesamorelin carries an FDA indication for HIV-associated lipodystrophy and remains accessible through lawful channels. Additional context on pathway distinctions is available in ghrh vs ghrp peptides and sermorelin and ipamorelin.
Statutory Threshold for Compounding
The statutory threshold for lawful compounding requires either an approved NDA or a Category 1 listing supported by adequate safety data. CJC-1295 and Ipamorelin satisfy neither condition. Provider experience and patient demand do not alter this statutory bar.
A pharmacy continuing to offer the stack after Category 2 listing operates on an incorrect legal interpretation or accepts enforcement risk. Either condition exposes the prescriber to liability through their own order. Related reporting explores epitalon peptide science for further regulatory context.
Evidence Limits
The Category 2 listing for CJC-1295 and Ipamorelin is documented in secondary regulatory analysis. No direct Federal Register notice or FDA docket link appears in the supplied records. The absence of a published combination-specific RCT is asserted by multiple independent sources and remains consistent with the regulatory status.
Benefit claims for this stack derive from clinic marketing, provider protocols, and theoretical mechanism reviews. Quality control data on gray-market samples originates from unpublished, non-peer-reviewed analysis reported in Scientific American.
